Royalty Pharma plc
RPRX
$33.35
$0.200.60%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 568.25M | 593.64M | 564.69M | 537.27M | 567.98M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 568.25M | 593.64M | 564.69M | 537.27M | 567.98M |
| Cost of Revenue | -127.14M | 164.04M | -227.60M | 212.43M | 583.60M |
| Gross Profit | 695.39M | 429.61M | 792.29M | 324.84M | -15.62M |
| SG&A Expenses | 110.71M | 67.59M | 56.72M | 54.71M | 57.65M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 34.07M | 232.13M | -170.38M | 267.64M | 641.75M |
| Operating Income | 534.18M | 361.51M | 735.07M | 269.63M | -73.77M |
| Income Before Tax | 433.43M | 334.35M | 806.36M | 194.38M | -4.27M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 433.43M | 334.35M | 806.36M | 194.38M | -4.27M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -195.08M | -126.14M | -262.37M | -92.37M | 9.05M |
| Net Income | 238.35M | 208.21M | 543.99M | 102.00M | 4.78M |
| EBIT | 534.18M | 361.51M | 735.07M | 269.63M | -73.77M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 0.55 | 0.35 | 1.22 | 0.23 | 0.01 |
| Normalized Basic EPS | 0.24 | 0.13 | 0.39 | 0.13 | -0.16 |
| EPS Diluted | 0.55 | 0.35 | 1.21 | 0.23 | 0.01 |
| Normalized Diluted EPS | 0.18 | 0.13 | 0.29 | 0.10 | -0.12 |
| Average Basic Shares Outstanding | 435.48M | 589.00M | 447.63M | 451.02M | 448.62M |
| Average Diluted Shares Outstanding | 578.10M | 589.00M | 592.73M | 596.91M | 597.48M |
| Dividend Per Share | 0.22 | 0.21 | 0.21 | 0.21 | 0.21 |
| Payout Ratio | 40.01% | 44.98% | 17.29% | 93.08% | 1,963.27% |